BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapies for advanced
breast cancer, is pleased to announce its lead product
candidate, Bria-IMT™, will be featured in two poster
sessions during the 2019 San Antonio Breast Cancer Symposium®
(SABCS) taking place December 10-14 in San Antonio, Texas.
The December 12th poster will summarize the data
of the Bria-IMT™ monotherapy study and the ongoing Phase I/IIa
clinical study of Bria-IMT™ in combination with immune checkpoint
inhibitors including pembrolizumab (KEYTRUDA®; manufactured by
Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012, in
advanced breast cancer. The December 13th poster
presentation will address early predictors of effectiveness of the
Bria-IMT™ regimen in advanced breast cancer.
"The early clinical findings for Bria-IMT™ in
combination with checkpoint inhibitors in advanced breast cancer
patients are very encouraging," said Dr. Bill Williams, President
& CEO of BriaCell. "We look forward to continuing our clinical
trial with the goal of developing novel treatments for advanced
breast cancer patients with no effective treatment options."
Details on the poster presentations are as
follows:
Program
Number: P3-09-08Presentation
Title: Efficacy and safety of a modified whole tumor
cell targeted immunotherapy in patients with advanced breast cancer
alone and in combination with immune checkpoint
inhibitors Session
Title: Poster Session
3Session
Date: Thursday, December
12, 2019Session
Time: 5:00 – 7:00p.m. CT
(6:00 – 8:00 p.m. ET)Location: Hall 1, Henry B.
Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX
78205 USA
Program Number:
P5-06-27Presentation Title: Circulating
cancer associated macrophage-like cells (CAMLs) are early
predictors of response to new line therapies in metastatic breast
cancerSession Title: Poster Session
5Session
Date: Friday, December 13,
2019Session
Time: 5:00 – 7:00p.m. CT
(6:00 – 8:00 p.m. ET)Location: Hall 1, Henry B.
Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX
78205 USA
The abstracts for these presentations will be
available online on the SABCS website at https://www.sabcs.org.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
About SABCS®
Since its inception in 1977, San Antonio Breast
Cancer Symposium (SABCS®) has grown to a five-day program that
covers the latest research on the experimental biology, etiology,
prevention, diagnosis, and treatment of breast cancer and
premalignant breast disease. The Symposium is attended by a large
international audience of researchers, health professionals,
physicians, oncologists, and those with a special interest in
breast cancer from over 90 countries.
To complement the clinical focus of the annual
SABCS®, Baylor College of Medicine became a joint sponsor of SABCS®
in 2005. Additionally, the Cancer Therapy & Research Center
(CTRC) at UT Health Science Center San Antonio and American
Association for Cancer Research (AACR), a prestigious scientific
organization known for its basic, translational and clinical cancer
research, began collaboration with SABC® in 2007. The Symposium was
renamed the CTRC-AACR San Antonio Breast Cancer Symposium.
For additional information on 2019 SABCS®,
please visit: https://www.sabcs.org.
About Creatv MicroTech
Creatv MicroTech is a privately-held company
with expertise in cancer diagnostics and cancer screening utilizing
whole blood. Creatv’s LifeTrac test collects
circulating tumor cells and a type of cancer associated
macrophage-like cells (CAMLs) from patients with solid
tumors. The LifeTrac test can detect cancer and determine the
optimal treatment, as well as providing precision diagnostics to
monitor treatment response, and provide timely prognosis.
For more information on Creatv MicroTech, please
visit our website: http://www.creatvBIO.com/
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024